A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,000 shares of CRVS stock, worth $68,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,000
Previous 14,900 46.31%
Holding current value
$68,880
Previous $26,000 46.15%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $72,093 - $121,392
53,010 New
53,010 $96,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $8,068 - $14,344
7,471 Added 4082.51%
7,654 $13,000
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.97 $258 - $543
183 New
183 $0
Q4 2022

Feb 14, 2023

BUY
$0.74 - $1.04 $751 - $1,055
1,015 New
1,015 $0
Q1 2022

May 16, 2022

BUY
$1.46 - $2.48 $491,238 - $834,433
336,465 Added 494.22%
404,545 $663,000
Q4 2021

Feb 14, 2022

BUY
$2.34 - $5.31 $90,796 - $206,038
38,802 Added 132.53%
68,080 $164,000
Q2 2021

Aug 16, 2021

SELL
$2.46 - $3.14 $86,082 - $109,878
-34,993 Reduced 54.45%
29,278 $78,000
Q1 2021

May 17, 2021

BUY
$2.86 - $4.77 $183,815 - $306,572
64,271 New
64,271 $198,000
Q3 2020

Nov 16, 2020

SELL
$2.6 - $5.37 $40,349 - $83,337
-15,519 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$2.01 - $4.05 $59,783 - $120,459
-29,743 Reduced 65.71%
15,519 $42,000
Q1 2020

May 15, 2020

BUY
$1.74 - $5.98 $49,342 - $169,580
28,358 Added 167.76%
45,262 $95,000
Q4 2018

Feb 14, 2019

SELL
$3.29 - $8.94 $14,344 - $38,978
-4,360 Reduced 20.5%
16,904 $62,000
Q3 2018

Nov 13, 2018

BUY
$8.58 - $11.4 $182,445 - $242,409
21,264 New
21,264 $0

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.